3 employees
KaNDy Therapeutics is a clinical-stage company focused on optimizing the potential of NT-814.
2017
$32M
from 4 investors over 4 rounds
KaNDy Therapeutics raised $32M on August 29, 2018
Investors: OrbiMed Advisors, Longitude Capital, Forbion and Advent Life Sciences